 Takeda Pharmaceutical Co. Ltd. TAK, 0.43 4502, 0.65 said Monday that it will acquire Hutchmeds HCM, 1.46 13, 1.10 experimental cancer treatment outside mainland China, Hong Kong and Macau, with plans to develop and commercialize fruquintinib. 